Krieger T, Pearson I, Bell J, Doherty J, Robbins P. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Diagn Pathol. 2020 Jan 30;15(1):6. doi: 10.1186/s13000-020-0927-9
Kawai AT, Martinez D, Saltus CW, Vassilev ZP, Soriano-Gabarro M, Kaye JA. Incidence of skeletal-related events in patients with castration-resistant prostate cancer: an observational retrospective cohort study in the US. Prostate Cancer. 2019 Jul 9. doi: 10.1155/2019/5971615
Saltus CW, Vassilev ZP, Zong J, Calingaert B, Andrews EB, Soriano-Gabarro M, Kaye JA. Incidence of second primary malignancies in patients with castration-resistant prostate cancer: an observational retrospective cohort study in the United States. Prostate Cancer. 2019 Feb 11;2019:4387415. doi: 10.1155/2019/4387415
Coon CD, Bokowy KL, Horblyuk R, Zisman RS, McLeod LD, Brown MT. The development and initial assessment of the strategy and leadership systems capability evaluation survey. Health Care Manag (Frederick). 2012 Oct 1;31(4):332-41.